Table 2. Pimasertib-related treatment-emergent adverse events by worst grade (occurring in ≥2 patients overall (all grades) by preferred term): safety population.

	Pimasertib 45 mg per day (n=10)			Pimasertib 60 mg per day (n=6)			Overall (n=16)
	Grade			Grade			Grade
System organ class preferred term	1/2	3	4	1/2	3	4	1/2	3	4
Patients with ≥1 TEAE (by worst grade)	5	5	0	2	2	2	7	7	2
Gastrointestinal disorders (n)
Diarrhoea	4	2	0	4	0	0	8	2	0
Vomiting	2	0	0	3	0	0	5	0	0
Nausea	2	0	0	2	0	0	4	0	0
Stomatitis	1	0	0	2	0	0	3	0	0
Skin and subcutaneous tissue disorders (n)
Rash	4	0	0	4	0	0	8	0	0
Dermatitis acneiform	1	0	0	1	0	0	2	0	0
General disorders and administration site conditions (n)
Asthenia	4	0	0	2	0	0	6	0	0
Mucositis	1	1	0	0	2	0	1	3	0
Eye disorders (n)
Serous retinal detachment	5	0	0	1	0	0	6	0	0
Blood and lymphatic system disorders (n)
Neutropenia	0	0	0	0	1	2	0	1	2
Metabolism and nutrition disorders (n)
Hypomagnesaemia	1	1	0	0	0	0	1	1	0

Abbreviation: TEAE=treatment-emergent adverse event.

Patients could have more than one event within a system organ class and a preferred term.